Table 5.
The summary of the efficacy of RARC vs LRC in the treatment of bladder cancer.
| RARC versus LRC in Bladder cancer | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intraoperative Security | Postoperative recovery | Oncologic outcomes | Complications | |||||||||||||
| Total operative time | Amount of blood loss | Transfusion rate | Hospital stay | Day to oral intake | Day to regular diet | Mean lymph node yield | Positive lymph node | Positive surgical margins | Cancer-related mortality | Intraoperative complication | Postoperative within 30days complication Grade ≤ II | Postoperative within 30days complication Grade ≥ III | Early complications within 30d | Postoperative 90 days or longer complication Grade ≤ II | Postoperative 90 days or longer complication Grade ≥ III | Overall surgery-related complication |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
means RARC decreased the effect vs LRC group; means that RARC has the same effect vs LRC group.
RARC, robotic assisted radical cystectomy; LRC, laparoscopic radical cystectomy.